Molecular Partners (NASDAQ:MOLN) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Molecular Partners (NASDAQ:MOLN) issued its quarterly earnings results on Thursday. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03), Zacks reports.

Molecular Partners Price Performance

Shares of Molecular Partners stock traded down $0.21 on Friday, hitting $4.50. The company had a trading volume of 1,050 shares, compared to its average volume of 4,388. Molecular Partners has a 52 week low of $3.36 and a 52 week high of $5.36. The company has a market cap of $181.71 million, a PE ratio of -2.34 and a beta of 1.03. The business has a 50-day simple moving average of $4.54 and a 200-day simple moving average of $4.17.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on MOLN shares. HC Wainwright initiated coverage on shares of Molecular Partners in a report on Tuesday, January 27th. They issued a “buy” rating and a $13.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research report on Monday, December 22nd. Finally, JPMorgan Chase & Co. cut their target price on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a research note on Monday, December 8th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Molecular Partners currently has a consensus rating of “Hold” and an average price target of $8.38.

Institutional Trading of Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by institutional investors.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.